Trial Profile
A Randomized, Double-Blind, Placebo and Active Comparator-Controlled Study of DS-5565 for Treatment of Neuropathic Pain Associated With Diabetic Peripheral Neuropathy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Feb 2024
Price :
$35
*
At a glance
- Drugs Mirogabalin (Primary) ; Pregabalin
- Indications Diabetic neuropathies; Neuropathic pain
- Focus Proof of concept; Therapeutic Use
- Sponsors Daiichi Sankyo Inc
- 16 Nov 2016 Results analysing secondary efficacy endpoints including modified brief pain inventory (BPI) score and average daily sleep interference score (ADSIS) presented at the 80th American College of Rheumatology and the 51st Annual Meeting of the Association of Rheumatology and Health Professionals.
- 30 Sep 2016 Results of key secondary outcomes presented at the 16th World Congress on Pain
- 03 May 2014 Results presented at the 66th Annual Meeting of the American Academy of Neurology.